As of 2025-08-10, the Intrinsic Value of Citius Pharmaceuticals Inc (CTXR) is -18.82 USD. This CTXR valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.23 USD, the upside of Citius Pharmaceuticals Inc is -1,630.24%.
Based on its market price of 1.23 USD and our intrinsic valuation, Citius Pharmaceuticals Inc (CTXR) is overvalued by 1,630.24%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -18.82 - -18.82 | -18.82 | -1,630.24% |
| P/E | (68.74) - (70.85) | (72.56) | -5999.1% |
| DDM - Stable | (27.57) - (101.08) | (64.32) | -5329.6% |
| DDM - Multi | (21.56) - (63.81) | (32.51) | -2743.1% |
| Market Cap (mil) | 13.74 |
| Beta | 2.56 |
| Outstanding shares (mil) | 11.17 |
| Enterprise Value (mil) | 13.71 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.45% |
| Cost of Debt | 5.00% |
| WACC | 7.70% |